Tandem Diabetes Care Stock Return On Equity

TNDM Stock

USD 30.81 0.07 0.23%

Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.

		Last Reported	Projected for Next Year
	Return On Equity	(0.71)	(0.67)

As of the 25th of November 2024, Return On Equity is likely to grow to -0.67.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tandem Diabetes Care Company Return On Equity Analysis

Tandem Diabetes' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Tandem Diabetes Return On Equity

-0.46

Most of Tandem Diabetes' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tandem Diabetes Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Tandem Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Tandem Diabetes is extremely important. It helps to project a fair market value of Tandem Stock properly, considering its historical fundamentals such as Return On Equity. Since Tandem Diabetes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tandem Diabetes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tandem Diabetes' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Intangible Assets	Long Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.88	0.9	-0.86	0.82	0.99	0.97	0.96	1.0	-0.02	0.78	0.97	0.78	0.56	0.85	0.98	0.93	0.9	0.58	0.6	0.97	0.96	0.97
Total Stockholder Equity	0.88		0.63	-0.76	0.65	0.88	0.9	0.72	0.9	-0.14	0.91	0.77	0.45	0.61	0.89	0.83	0.81	0.9	0.56	0.63	0.92	0.92	0.74
Net Debt	0.9	0.63		-0.79	0.81	0.89	0.87	0.97	0.88	0.21	0.54	0.93	0.89	0.45	0.69	0.89	0.84	0.76	0.56	0.53	0.84	0.84	0.95
Retained Earnings	-0.86	-0.76	-0.79		-0.9	-0.89	-0.81	-0.81	-0.85	-0.19	-0.85	-0.92	-0.78	-0.24	-0.87	-0.84	-0.94	-0.89	-0.78	-0.82	-0.78	-0.78	-0.83
Accounts Payable	0.82	0.65	0.81	-0.9		0.84	0.73	0.83	0.8	0.22	0.72	0.87	0.8	0.11	0.77	0.77	0.87	0.78	0.65	0.67	0.72	0.72	0.81
Net Receivables	0.99	0.88	0.89	-0.89	0.84		0.98	0.94	0.99	-0.01	0.82	0.96	0.76	0.54	0.9	0.97	0.96	0.93	0.66	0.67	0.97	0.97	0.95
Short Term Investments	0.97	0.9	0.87	-0.81	0.73	0.98		0.92	0.99	-0.08	0.78	0.91	0.69	0.67	0.86	0.96	0.9	0.89	0.56	0.59	0.98	0.98	0.93
Total Liab	0.96	0.72	0.97	-0.81	0.83	0.94	0.92		0.94	0.06	0.62	0.97	0.88	0.49	0.76	0.95	0.89	0.83	0.55	0.54	0.91	0.9	0.98
Total Current Assets	1.0	0.9	0.88	-0.85	0.8	0.99	0.99	0.94		-0.05	0.8	0.95	0.74	0.6	0.87	0.97	0.92	0.91	0.58	0.6	0.98	0.98	0.95
Short Term Debt	-0.02	-0.14	0.21	-0.19	0.22	-0.01	-0.08	0.06	-0.05		-0.08	0.09	0.12	-0.19	-0.07	-0.17	-0.03	-0.06	0.23	0.38	-0.08	-0.09	0.0
Common Stock	0.78	0.91	0.54	-0.85	0.72	0.82	0.78	0.62	0.8	-0.08		0.74	0.47	0.35	0.92	0.76	0.84	0.9	0.59	0.76	0.79	0.79	0.66
Property Plant Equipment	0.97	0.77	0.93	-0.92	0.87	0.96	0.91	0.97	0.95	0.09	0.74		0.88	0.42	0.81	0.95	0.93	0.87	0.63	0.63	0.89	0.88	0.98
Current Deferred Revenue	0.78	0.45	0.89	-0.78	0.8	0.76	0.69	0.88	0.74	0.12	0.47	0.88		0.13	0.56	0.81	0.79	0.64	0.47	0.42	0.64	0.63	0.89
Intangible Assets	0.56	0.61	0.45	-0.24	0.11	0.54	0.67	0.49	0.6	-0.19	0.35	0.42	0.13		0.39	0.55	0.35	0.46	0.14	0.17	0.69	0.68	0.49
Long Term Debt	0.85	0.89	0.69	-0.87	0.77	0.9	0.86	0.76	0.87	-0.07	0.92	0.81	0.56	0.39		0.83	0.92	0.97	0.73	0.83	0.89	0.89	0.76
Net Tangible Assets	0.98	0.83	0.89	-0.84	0.77	0.97	0.96	0.95	0.97	-0.17	0.76	0.95	0.81	0.55	0.83		0.93	0.89	0.54	0.53	0.94	0.94	0.97
Long Term Debt Total	0.93	0.81	0.84	-0.94	0.87	0.96	0.9	0.89	0.92	-0.03	0.84	0.93	0.79	0.35	0.92	0.93		0.92	0.7	0.75	0.88	0.88	0.91
Capital Surpluse	0.9	0.9	0.76	-0.89	0.78	0.93	0.89	0.83	0.91	-0.06	0.9	0.87	0.64	0.46	0.97	0.89	0.92		0.73	0.78	0.92	0.92	0.82
Deferred Long Term Liab	0.58	0.56	0.56	-0.78	0.65	0.66	0.56	0.55	0.58	0.23	0.59	0.63	0.47	0.14	0.73	0.54	0.7	0.73		0.8	0.58	0.58	0.54
Short Long Term Debt	0.6	0.63	0.53	-0.82	0.67	0.67	0.59	0.54	0.6	0.38	0.76	0.63	0.42	0.17	0.83	0.53	0.75	0.78	0.8		0.61	0.62	0.51
Net Invested Capital	0.97	0.92	0.84	-0.78	0.72	0.97	0.98	0.91	0.98	-0.08	0.79	0.89	0.64	0.69	0.89	0.94	0.88	0.92	0.58	0.61		1.0	0.9
Net Working Capital	0.96	0.92	0.84	-0.78	0.72	0.97	0.98	0.9	0.98	-0.09	0.79	0.88	0.63	0.68	0.89	0.94	0.88	0.92	0.58	0.62	1.0		0.89
Capital Stock	0.97	0.74	0.95	-0.83	0.81	0.95	0.93	0.98	0.95	0.0	0.66	0.98	0.89	0.49	0.76	0.97	0.91	0.82	0.54	0.51	0.9	0.89

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Tandem Diabetes

Return On Equity Over Time

Tandem Total Stockholder Equity

Total Stockholder Equity

160.8 Million

At this time, Tandem Diabetes' Total Stockholder Equity is very stable compared to the past year.

Based on the latest financial disclosure, Tandem Diabetes Care has a Return On Equity of -0.4596. This is 98.08% lower than that of the Health Care Equipment & Supplies sector and 94.74% lower than that of the Health Care industry. The return on equity for all United States stocks is 48.26% higher than that of the company.

Tandem Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tandem Diabetes' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics of similar companies.

Tandem Diabetes is currently under evaluation in return on equity category among its peers.

Tandem Diabetes ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tandem Diabetes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tandem Diabetes' managers, analysts, and investors.

Environmental

Governance

Social

Tandem Fundamentals

	Return On Equity	-0.46
	Return On Asset	-0.0969
	Profit Margin	(0.15) %
	Operating Margin	(0.11) %
	Current Valuation	2.03 B
	Shares Outstanding	65.68 M
	Shares Owned By Insiders	0.76 %
	Shares Owned By Institutions	99.24 %
	Number Of Shares Shorted	8.39 M
	Price To Earning	494.25 X
	Price To Book	8.51 X
	Price To Sales	2.37 X
	Revenue	747.72 M
	Gross Profit	412.99 M
	EBITDA	(194.66 M)
	Net Income	(222.61 M)
	Cash And Equivalents	608.73 M
	Cash Per Share	9.47 X
	Total Debt	415.67 M
	Debt To Equity	1.00 %
	Current Ratio	4.80 X
	Book Value Per Share	3.62 X
	Cash Flow From Operations	(31.81 M)
	Short Ratio	6.85 X
	Earnings Per Share	(1.94) X
	Target Price	51.3
	Number Of Employees	2.4 K
	Beta	1.37
	Market Capitalization	2.02 B
	Total Asset	952.66 M
	Retained Earnings	(951.8 M)
	Working Capital	552.73 M
	Current Asset	106.98 M
	Current Liabilities	26.52 M
	Net Asset	952.66 M

About Tandem Diabetes Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:

How To Invest In Tandem

Details

Is Tandem Stock a good investment?

Details

What is Tandem Diabetes' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Tandem Diabetes Piotroski F Score and Tandem Diabetes Altman Z Score analysis.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.37)

Earnings Share

(1.94)

Revenue Per Share

13.082

Quarterly Revenue Growth

0.314

Return On Assets

(0.1)

The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tandem Diabetes Care Stock Return On Equity

Tandem Diabetes Care Company Return On Equity Analysis

Return On Equity

Net Income

Total Equity

Current Tandem Diabetes Return On Equity

Tandem Return On Equity Driver Correlations

Tandem Total Stockholder Equity

Total Stockholder Equity

160.8 Million

Tandem Return On Equity Peer Comparison

Tandem Diabetes ESG Sustainability

Tandem Fundamentals

About Tandem Diabetes Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY